• Participants must meet all the following criteria:

• Be aged 18 to 85 years inclusive at the time of consent.

• Provide informed consent prior to any study procedures, as stipulated by local laws, Ethics Committee (EC) and Regulatory Authority (RA) guidelines.

• Be willing and able to follow all study instructions, attend all study visits, and complete all study assessments.

• Have a clinical diagnosis of ME in the study eye secondary to non-infectious uveitis, retinal vein occlusion, diabetic retinopathy or cataract surgery.

• If currently receiving systemic corticosteroid therapy or immunosuppressive therapy (or any combination thereof), be on a stable dose of therapy for at least 3 months prior to Screening and during the study.

• Have a Central Subfield Thickness (CST) of ≥ 350 µm.

• Have a Best Corrected Visual Acuity (BCVA) in the study eye of:

‣ ≤ 20/32 (Feet); logMAR ≥ 0.2

• Have media clarity and pupillary dilation sufficient for adequate visualization and assessment of the study eye.

• Be willing to avoid disallowed medications and treatments for the duration of the study.

⁃ Agree to follow appropriate contraception requirements from screening until 3 months after the last dose of the study drug.

∙ Participants assigned female at birth who are of child-bearing potential (OCBP) must agree to a pregnancy test at Screening and prior to each dose of investigational medicinal product (IMP) and use an acceptable method of birth control including oral, transdermal, injectable, or implantable hormonal contraception, intrauterine device, abstinence from intercourse with partner assigned male at birth, or surgical sterilisation of partner assigned male at birth.

‣ Participants assigned female at birth are not OCBP if they have had a hysterectomy, bilateral oophorectomy, bilateral tubal ligation, or are post-menopausal by at least 12 months. Post-menopausal status of amenorrheic female participants should be confirmed at Screening through testing of follicle-stimulating hormone (FSH) as per analysing laboratory threshold.

‣ Participants assigned male at birth with a partner OCBP must be surgically sterile for at least 3 months prior to starting study drug, or ensure their partner uses contraception as outlined above, and must use a male condom. Participants assigned male at birth must not donate sperm from Screening until 3 months after the last dose of IMP.

‣ Participants who have practiced true abstinence for at least 1 year due to usual and preferred lifestyle choice are exempt from contraceptive requirements. If a participant who is abstinent becomes sexually active, they must agree to use appropriate contraception as described above.